DMR News

Advancing Digital Conversations

FDA Approves Prenosis Software as First AI Tool for Sepsis Diagnosis

ByHuey Yee Ong

Apr 5, 2024
FDA Approves Prenosis Software as First AI Tool for Sepsis Diagnosis

FDA Approves Prenosis Software as First AI Tool for Sepsis Diagnosis

Prenosis, a health technology company, revealed that their artificial intelligence-powered diagnostic tool for sepsis has gained approval from the U.S. Food and Drug Administration (FDA) on Wednesday, April 3rd.

Sepsis, a condition marked by the body’s extreme response to infection, poses a significant challenge in diagnosis and treatment, often resulting in fatalities. According to data from the Centers for Disease Control and Prevention, over 350,000 adults suffer fatal outcomes or are directed to hospice care due to sepsis annually, underscoring the urgent need for improved diagnostic capabilities.

Prenosis’s Approach to Sepsis Detection

Prenosis’ innovative solution, known as Sepsis ImmunoScore, was given the green light through the FDA’s De Novo pathway, marking a notable milestone as no similar tool had been approved before.

The Sepsis ImmunoScore tool utilizes a comprehensive approach, analyzing 22 distinct parameters such as temperature, heart rate, and cell counts to assist healthcare providers in evaluating a patient’s risk of sepsis. Traditionally, clinicians have had to monitor these parameters individually, but Prenosis’ AI-driven system streamlines this process by simultaneously assessing all markers to generate an overall risk score.

Furthermore, the tool categorizes patients into four risk groups, providing valuable insights into the likelihood of clinical deterioration. Built on Prenosis’ Immunix platform, which draws from a vast dataset comprising over 100,000 blood samples from 25,000 patients, the Sepsis ImmunoScore integrates seamlessly into electronic health records, ensuring accessibility and ease of use for clinicians.

Other AI-based Solutions

While Prenosis celebrates its pioneering achievement, it’s important to note that other organizations have also ventured into the development of AI-based sepsis diagnostic tools.

  • Johns Hopkins University:
    • Introduced an AI system for early detection of sepsis symptoms.
    • Published impressive results in Nature Medicine in 2022, demonstrating early detection hours before conventional methods.
  • Epic Systems:

In contrast, Prenosis opted for a meticulous approach, prioritizing FDA approval before bringing its product to market.

Despite the tool being ready approximately three years ago, the company remained steadfast in its commitment to regulatory compliance and safety. This approach aligns with the FDA’s updated guidance, issued in September 2022, which emphasizes the importance of official authorization for software analyzing patient-specific medical data to detect life-threatening conditions like sepsis. Prenosis invested around 18 months in demonstrating the safety and efficacy of Sepsis ImmunoScore to the FDA, a process culminating in the recent approval.

Prenosis intends to proceed with further studies to validate the the tool’s accuracy and assess its impact on clinical decision-making. Having obtained FDA approval, the company is now prepared to introduce Sepsis ImmunoScore to hospitals across the United States, with plans for global expansion in the pipeline.

Related News:

Featured Image courtesy of Getty Images/iStockphoto

Huey Yee Ong

Hello, from one tech geek to another. Not your beloved TechCrunch writer, but a writer with an avid interest in the fast-paced tech scenes and all the latest tech mojo. I bring with me a unique take towards tech with a honed applied psychology perspective to make tech news digestible. In other words, I deliver tech news that is easy to read.

Leave a Reply

Your email address will not be published. Required fields are marked *